Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 49 Carcinoma, Non-Small-Cell Lung 34 Carcinoma, Renal Cell 26 Neoplasms 13 Neoplasm Metastasis 13 Lung Neoplasms 12 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Carcinoma, Hepatocellular 11 Adenocarcinoma Of Esophagus 11 Colorectal Neoplasms 10 Hodgkin Disease 7 Esophageal Neoplasms 7 Carcinoma, Transitional Cell 7 Skin Neoplasms 6 Sarcoma 6 Brain Neoplasms 6 Triple Negative Breast Neoplasms 5 Recurrence 5 Kidney Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Clear-cell metastatic renal cell carcinoma 5 Carcinoma, Merkel Cell 5 Breast Neoplasms 5 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Multiple Myeloma 4 Glioblastoma 4 Colonic Neoplasms 4

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡